Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)
Key facts
- Where
- Bodo, Drammen, Graalum, Lorenskog és Trondheim, NorvégiaSee the 5 sites
- Phase
- 3. fázis
Where in Norvégia
- Nordlandssykehuset HFBodo, NorvégiaTaking people
- Drammen SykehusDrammen, NorvégiaTaking people
- Sykehuset Oestfold HF KalnesGraalum, NorvégiaTaking people
- Akershus University HospitalLorenskog, NorvégiaTaking people
- St. Olavs hospital HFTrondheim, NorvégiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Akershus University Hospital
- Trial code
- EU 2023-509022-22-00
- Record updated
- 2026. május 13.
- Original description
To investigate the efficacy and safety of adding antiplatelet theraphy to standard thromboprophylaxis on thrombotic disease in patients with pancreatic ductal cancer.Read full original descriptionShow less
To investigate the efficacy and safety of adding antiplatelet theraphy to standard thromboprophylaxis on thrombotic disease in patients with pancreatic ductal cancer.
Inclusion: Participants are >18 years of age; Patients with locally advanced, metastatic or recurrent (after intended therapeutic treatment) pancreatic ductal adenocarcinoma; Patients where there is planned treatment or already receive treatment for their pancreatic ductal cancer; Patients receiving neoadjuvant chemotherapy before intended curative surgery.
Exclusion: Known previous heparin induced thrombocytopenia – HIT; Current use of antiplatelet therapy or disease with indication for antiplatelet therapy not yet initiated; Known hypersensitivity to clopidogrel or dalteparin; Current use of full dose anti-coagulation or disease with indication of full dose anti-coagulation. Patients already on primary prophylaxis can be included; Known allergies to study medication; Active bleeding or severe risk of bleeding; Clinically significant liver disease (e.g., chronic active hepatitis, or cirrhosis); Platelets <30×10^9/L; Known CYP2C19 genotype that influences clopidogrel metabolism (genotyping not necessary); Severe intestinal malabsorption; Known pregnancy (pregnancy test is not necessary).